High-Risk Care Varies Widely

Anita T. Shaffer @Shaffer1
Published: Tuesday, May 31, 2011
Howard M. Sandler, MD

Howard M. Sandler, MD

Radiation therapy (RT) used in combination with androgen deprivation therapy (ADT) continues to be a viable strategy for treating patients with localized, high-risk prostate cancer but many clinicians are not employing it—even though guidelines suggest they should.

Howard M. Sandler, MD, professor and chair of the Department of Radiation Oncology at Cedars- Sinai Medical Center in Los Angeles, California, made those points during the Interdisciplinary Prostate Cancer Congress held March 26 in New York City.

Sandler cited an analysis that Cooperberg et al conducted based on the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry (J Clin Oncol. 2010;28(7):1117-1123) through 2007.

The researchers found the use of primary ADT for high-risk patients has risen to approximately 40%, while the use of external-beam RT declined to approximately 20%. High-risk patients, who comprise an estimated 15% to 25% of all prostate cancer patients, are most likely to die of the disease.

“It is kind of shocking to me that when you go all across the country that’s what people are getting,” Sandler said. “Primary hormonal therapy really should be used sparingly in these patients. It’s not a trivial effect adding radiation to these patients. The magnitude of benefit is on the order of radical prostatectomy for localized prostate cancer.”

Treatment Trends in High-Risk Patients

Treatment Trends

Adapted from Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.

Matthew R. Cooperberg, MD, MPH, an assistant professor of Urology at the University of California, San Francisco, said in an interview that guidelines support RT or surgery for high-risk patients, but there are few studies comparing outcomes across treatment options.

“The trend that many men with localized high-risk prostate cancer are not getting an opportunity at a cure is, I think, troubling,” said Cooperberg, noting that other studies found similar treatment patterns. “…I think both surgery and radiation therapy are underutilized. The fact is, men with high-risk disease very frequently need multimodal therapy.”

Padraig Warde, MCChB, a professor of Radiation Oncology at the University of Toronto in Canada, led a large National Cancer Institute of Canada study that established the benefits of combination RT and hormonal therapy for high-risk patients. After 7 years of follow-up, 74% of men who received the combination therapy were still alive, compared with 66% who received hormone therapy alone, the researchers found. (abstract CRA4504 from J Clin Oncol. 2010;28 [suppl 18]).

“I think it’s certainly a practice-changer, particularly in areas in which there was a lot of skepticism about the value of radiation in certain people,” Warde said.


Matthew R. Cooperberg

Matthew R. Cooperberg, MD, MPH

Discrepancy between guidelines and community practice:
There is a huge amount of variation in terms of what actually gets done in community practice. There are some practices that do a lot of surgery. There are some practices that use frequent radiation therapy. Others favor brachytherapy, and still others cryotherapy. The guidelines endorse all of these as options because there have been few studies comparing them.

Aside from the instance of hormonal therapy for clinically localized disease, it’s hard to say that the practice is not consistent with the guidelines. It’s just that there is tremendous variation. The guidelines are, by necessity and sort of by definition, fairly vague because we don’t have many studies yet doing the kind of comparisons that need to be done.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication